TABLE 2.

Liposomal formulations of anticancer drugs in phase I clinical trials

Product Name	Encapsulated Drugs	Type of Liposomes	Indications	Lipid Composition	Particle Size	Status	Reference
					nm
Alocrest	Vinorelbine	Optisomes	NSCLC and breast cancers, non-Hodgkin’s lymphoma, Hodgkin’s disease	Sphingomyelin and cholesterol	—	Phase I	NCT00364676a (accessed on 14/4/15); Semple et al. (2005); Cattaneo et al. (2010);
Aroplatin	Analog of cisplatin	MLVs	Advanced pancreatic and colorectal cancer, malignant pleural mesothelioma, advanced solid malignancies	DMPC and DMPG	—	Phase I/II	NCT00043199a (accessed on 14/4/15); Lu et al. (2005); Dragovich et al. (2006)
ATI-1123	Docetaxel	Protein stabilized liposomes	NSCLC, gastric, pancreatic cancer, and soft tissue sarcoma	Phospholipids, cholesterol, human serum albumin, and sucrose	60-80	Phase I	Mahalingam et al. (2014)
Brakiva (TLI)	Topotecan	Optisomes	Small cell lung, ovarian cancers and advanced solid tumors	Sphingomyelin and cholesterol	100	Phase I	NCT00765973a (accessed on 14/4/15); Tardi et al. (2000)
NanoVNB	Vinorelbine	PEGylated liposomes	Advanced solid tumors	DSPC, DSPE-PEG2000Da, cholesterol	98	Phase I	Yang et al. (2012b); Lin et al. (2013)
MCC-465	Doxorubicin	Antibody conjugated PEGylated liposomes	Stomach cancer	DPPC, maleimidated DPPE, PEG, GAH	143	Phase I	Hamaguchi et al. (2004); Matsumura et al. (2004)
SGT-53	p53 DNA plasmid	Anti-TfR conjugated cationic liposomes	Solid tumors	DOTAP and DOPE	114	Phase I	NCT0047061a (accessed on 15/4/15); Xu et al. (2001); Camp et al. (2013); Kim et al. (2015)
TKM-080301 (TKM-PLK1)	PLK1 siRNA	Cationic PEGylated liposomes	Gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, hepatocellular carcinoma	DSPC, DLin-MC3-DMA, DMG-PEG, and cholesterol	80-140	Phase I/II	NCT01262235a (accessed on 15/4/15); Tam et al. (2013); Leung et al. (2014)

^aClinicalTrials.gov identifier

DMPC, 1,2-dimyristoyl phosphatidylcholine; DMPG, 1,2-dimyristoyl phosphatidylglycerol; DPPE, 1,2-dipalmitoyl phosphatidylethanolamine; GAH, human monoclonal antibody; NSCLC, non-small cell lung cancer; DLin-MC3-DMA, heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate; DMG-PEG, polyethylene glycol-dimyristolglycerol; TfR, transferrin receptor